Corporate Governance

Carol Burt has served as a ResMed director since November 2013 and is chair of the audit and compliance oversight committees. She is also a member of the nominating and governance committee.

Ms. Burt, principal of Burt-Hilliard Investments since 2008, is a private investor with more than 35 years of experience in corporate governance, operations, strategy, finance, mergers and acquisitions, and investment banking. Since 2013, Ms. Burt has served as a senior advisor and a member of the operating council of Consonance Capital Partners, a New York-based private equity firm focused on investments in the healthcare industry. Ms. Burt serves on the boards of IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, where she chairs the leadership development and compensation committee and is a member of the audit committee; and two private companies, Global Medical Response and WellDyne.

Prior to their sale, Ms. Burt served on the public boards of four NYSE companies: Envision Healthcare, Transitional Hospitals, Vanguard Health Systems, WellCare Health Plans, and private equity-backed KEPRO. Through her public board service, Ms. Burt has served, or currently serves, as chair of audit, compensation, compliance and nominating and governance committees.

Ms. Burt was formerly senior vice president corporate finance and development of WellPoint, Inc. (now Elevance Health, NYSE: ELV) where she was part of the executive team that built WellPoint from a single state health plan to one of the leading health benefits companies in the U.S., at the time ranking in the top 35 Fortune 500 companies. Ms. Burt was responsible for, among other things, corporate strategic planning and execution, mergers and acquisitions, strategic and venture investments, financial planning and analysis, budgeting and forecasting, administrative accounting, treasury and chief investment officer, business information services and corporate real estate management. In addition, WellPoint’s financial services and international insurance business units reported to her.

Before WellPoint, Ms. Burt was senior vice president and treasurer of American Medical Response. Previously, she spent 16 years at Chase Securities, Inc., now JP Morgan Chase & Co (NYSE: JPM), most recently as founder, managing director and head of the Health Care Banking Group.

Ms. Burt is Co-Chair of the Emeritus Trustee program for the Colorado Chapter of The Nature Conservancy. Ms. Burt is a member of Women Corporate Directors, and the International Women’s Forum. Her philanthropic activities focus on mentoring women for leadership positions and environmental causes.

Ms. Burt graduated magna cum laude from the University of Houston, earning a Bachelor of Business Administration.

Jan De Witte has served as ResMed’s director since May 2019, and is a member of its audit and compliance oversight committees.

Mr. De Witte is President, CEO, and a director of Integra LifeSciences (NASDAQ: IART), a global leader in regenerative tissue technologies and neurosurgical solutions.

Mr. De Witte serves on the board of directors of the Advanced Medical Technology Association (AdvaMed). From 2018 until 2022, Mr. De Witte served as chair of the board of Hangar K, a non-profit innovation and co-creation hub bringing together start-ups, young growth companies, and established companies in the Flanders (Belgium) region with the aim to accelerate innovation and growth, with a focus on digital technologies in EdTech and GameTech. Over that same period, he also served as a board member of Ghent University (Belgium).

Mr. De Witte has served in a variety of operational and business leadership roles over the past 30 years. Most recently, he served as CEO and a member of the board of directors of Barco (EBR: BAR), a global leader in advanced visualization solutions for healthcare, entertainment, and enterprise, with headquarters in Belgium. Before joining Barco in October 2016, Mr. De Witte was an officer of the General Electric Company (NYSE: GE), and CEO of its healthcare division’s software and solutions business. During his 17-year tenure with GE, he worked in management and CEO roles in manufacturing, supply chain, quality/lean six sigma, services, and software solutions, covering business responsibilities across Europe, Middle East, China, Asia-Pacific, and the Americas. While at GE, he and his family lived in Belgium, London, Chicago, Milwaukee, and Paris.

Before GE, Mr. De Witte held operational management positions in supply chain and manufacturing at Procter & Gamble (NYSE: PG) in Europe. He also served as senior consultant with McKinsey & Company serving clients in the airline, process, and high-tech industries across Europe.

Mr. De Witte holds a Master of Science degree in electromechanical engineering with Greatest Distinction from the KU Leuven in Belgium, and an MBA from Harvard Business School.

Karen Drexler has served as a ResMed director since November 2017. She is chair of the compensation committee, and a member of the nominating and governance committee.

Ms. Drexler is a serial entrepreneur with expertise in the fields of digital health, medical devices, and diagnostics. Currently, she serves on the boards of Outset Medical (NASDAQ: OM), a medtech company innovating dialysis treatment, where she is a member of both the compensation and nomination and governance committees; Tivic Health, (NASDAQ: TIVC), a bioelectric medicine company focused on relief of congestion and sinus pain, where she chairs the compensation and nomination and corporate governance committees and serves on the audit committee; and EBR Systems, Inc. (ASX: EBR), maker of a wireless cardiac pacing system for people with heart failure, where she chairs the remuneration and governance committee.

Ms. Drexler is also on the board of two private companies: VIDA Diagnostics, the leading company in AI-powered lung intelligence solutions; and Huma.ai, a company using natural language queries to extract unique insights from complex medical data.

From 2016 to 2020, Ms. Drexler was the CEO and a board member of Sandstone Diagnostics, Inc., a private company developing instruments and consumables for point-of-care medical testing. From 2011 to 2017, she served as board chair of Hygieia, Inc., a digital insulin therapy company, and remains an advisor to the CEO. She also acts as a senior strategic advisor for other early-stage companies, and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University.

Ms. Drexler is an active mentor and advisor with Astia, a global nonprofit that supports high-potential female founders. She is a founding member of Astia Angels, a network of individual investors who fund such founders, and a lead mentor with StartX, the Stanford University incubator. She is also on the Life Science and Women’s Health Councils for Springboard, an accelerator for women-led technology-oriented companies. Through her work with Astia, Springboard, and StartX, she interacts with many promising young medtech companies.

Ms. Drexler was founder, president, and CEO of Amira Medical Inc., a private company focused on minimally invasive glucose monitoring technology, from 1996 until it was sold to Roche Holding AG in 2001. Before Amira Medical, she held management roles at LifeScan and played a key role in its sale to Johnson & Johnson (NYSE: JNJ).

Ms. Drexler graduated magna cum laude with a B.S.E. in chemical engineering from Princeton University, and earned an M.B.A. with honors from the Stanford University Graduate School of Business.

Peter Farrell is ResMed’s founder and chair emeritus. He has been a director since ResMed’s inception in May 1989, and served as the chair of our board of directors until January 2023, when he became chair emeritus. Dr. Farrell served as CEO from July 1990 until December 2007, and from February 2011 until March 2013. He served as executive board chairman from December 2007 until February 2011, and from March 2013 through December 2013. Since January 1, 2014, he has been a non-officer employee of ResMed.

Before founding ResMed, Dr. Farrell served as vice president of research and development at various subsidiaries of Baxter International, Inc. (NYSE: BAX), from July 1984 to June 1989, and managing director of the Baxter Center for Medical Research Pty Ltd., a Baxter subsidiary, from August 1985 to June 1989. From January 1978 to December 1989, he was foundation director of the Graduate School for Biomedical Engineering at the University of New South Wales, where he currently serves as a visiting professor and was formerly chair of the UNSW Centre for Innovation and Entrepreneurship. He served on the Visiting Committee of the Harvard/MIT Health Sciences & Technology Program from 1998 through 2018, and currently serves on the MIT Dean of Engineering’s Advisory Council.

Dr. Farrell serves on one additional public company board: Arcturus Therapeutics Ltd (NASDAQ: ARCT), a self-replicating mRNA therapeutics company, as board chair and member of its compensation and nominating and governance committees.

Dr. Farrell also serves on the board of three privately held companies: Immunicom Inc., a medtech company developing blood-filtering Immunopheresis® technology to treat cancer and other terminal diseases; ProtoStar, a medical rehabilitation company; and WaveGuide, a startup leveraging nuclear magnetic resonance technology developed within Harvard’s School of Physics, as its chair.

Finally, Dr. Farrell sits on the Board of Trustees of Scripps Research, and on two faculty advisory boards at the University of California, San Diego: the Rady Business School and the Jacobs Engineering School.

Dr. Farrell is a fellow or honorary fellow of several professional bodies. In 2012, he became an elected member of the U.S. National Academy of Engineering and joined the board of trustees of Scripps Research. He was named 2005 U.S. National Entrepreneur of the Year for Health Sciences, 2001 Australian Entrepreneur of the Year, and 1998 San Diego Entrepreneur of the Year for Health Sciences. He has served on the Executive Council of the Division of Sleep Medicine at Harvard Medical School since 1998, served as vice-chairman from 2000 until 2010, and chairman until May 2013.

Dr. Farrell has a B.E. in chemical engineering with honors from the University of Sydney, an S.M. in chemical engineering from MIT, a Ph.D. in chemical engineering and bioengineering from the University of Washington, Seattle, and a D.Sc. from the University of New South Wales, Sydney, for research contributions in the field of treatment with the artificial kidney.

Michael “Mick” Farrell was appointed ResMed’s CEO and has served as a director since March 2013. In January 2023, he was appointed chairman of our board of directors. Mick joined the company in 2000, serving as president of the Americas region from 2011 to 2013, senior vice president of the global sleep apnea business unit from 2007 to 2011, and various senior roles in marketing and business development.

Before joining ResMed, Mick worked in management consulting, biotechnology, chemicals and metals manufacturing at companies including Arthur D. Little, Sanofi Genzyme, Dow Chemical, and BHP.

Mick serves on the board of directors of the Advanced Medical Technology Association (AdvaMed) and Zimmer Biomet (NYSE: ZBH), a global provider of implantable musculoskeletal medical devices. He is a member of two committees at Zimmer Biomet: the compensation and management development committee, as well as the quality, regulatory, and technology committee, of which he is chair. Mick also volunteers as a trustee for non-profit organizations: UC San Diego Foundation, Rady Children’s Hospital, and Father Joe’s Villages’ project for the homeless in San Diego, California.

Mick holds a Bachelor of Engineering with first-class honors from the University of New South Wales, a Master of Science in chemical engineering from the Massachusetts Institute of Technology (MIT), and a Master of Business Administration from the MIT Sloan School of Management.

Harjit Gill has served as a ResMed director since November 2018, and is a member of the audit and compensation committees.

Ms. Gill is CEO of the Asia Pacific Medical Technology Association (APACMed), the first and only regional association to provide a unified voice for the medical device, equipment, and in-vitro diagnostics industry in Asia Pacific. She also holds several board positions: Since 2019 she has been a member of the Innovation Board of Directors at MAS Holdings, one of the largest apparel manufacturers in Southeast Asia with 53 manufacturing facilities in 17 countries and 93,000 employees. Since January 2022, she has been a board member at Amway, a global leader in home, health, and beauty products.

From 2012 to 2015, she was a board member of the Singapore International Chamber of Commerce. From 2017 to 2019 she was a member of the board of directors of Apollo Education and Training, a company providing English teaching in Vietnam. From 2014 to 2015 she was a member of the World Economic Forum South East Asia Council and in 2018 she was the Chapter Chair Gold of the YPO Singapore Chapter. From 2016 to 2019, she was an advisor to Delmedica Investments, a Singapore-based company focused on respiratory healthcare and inventors of the X-Halo breath thermometer.

Ms. Gill has a Bachelor of Arts (honors) in combined studies from the University of Manchester.

John Hernandez has served as a ResMed director since November 2021, and is a member of the compliance oversight committee.

Dr. Hernandez is head of clinical research, health economics, and outcomes research at Google (NASDAQ: GOOGL). He joined Alphabet in 2016 where he has built and led teams at Verily and Google leveraging artificial intelligence to assist in promoting healthy lifestyles, diagnosing cancer, preventing blindness, and more. He serves on the board of directors of Carmat, SA (ALCAR.PA), a publicly traded French artificial heart company, where he is a member of the audit and R&D committees.

Dr. Hernandez is a medical device and digital health executive with over 30 years of experience in clinical research, health economics, market access, and global commercial strategy. Prior to joining Alphabet, he was vice president of global health economics and outcomes research at Abbott Laboratories (NYSE: ABT), and vice president of health economics and clinical research at Boston Scientific Corporation (NYSE: BSX). He has also been an adjunct faculty member at Stanford University and served in health services research, strategy consulting, and health policy roles at the RAND Corporation, Quintiles, PwC, and the American Society of Internal Medicine (now ACP). 

Dr. Hernandez is widely published in scientific journals and is a frequent healthcare lecturer. He holds a PhD and Masters in Health Policy from the RAND Graduate School in Santa Monica, Calif., and a bachelor’s in political science from the University of North Carolina at Chapel Hill.

Rich Sulpizio has served as a ResMed director since August 2005. He is chair of the nominating and governance committee, and a member of the audit and compensation committees.

Mr. Sulpizio retired as president and chief operating officer of Qualcomm, Inc. (NASDAQ: QCOM) in 2001. He served on Qualcomm’s board of directors from 2000 until 2007. Mr. Sulpizio joined Qualcomm in 1991 and in 1994, was appointed president of Qualcomm Wireless Business Solutions. Four years later, he became Qualcomm’s president and COO. In 2002, he rejoined Qualcomm to serve as interim president of Qualcomm China and then took the helm of Qualcomm Europe in 2004. He was appointed as president in 2005 of MediaFLO USA, Inc. a wholly-owned subsidiary of Qualcomm, and was chartered with overseeing the development and deployment of MediaFLO technology and bringing multimedia services to the wireless industry. His last assignment, from December 2009 to November 2013, was president and CEO of Qualcomm Enterprise Services (QES), which was sold to a private equity firm.

Before joining Qualcomm, Mr. Sulpizio worked at Unisys Corporation (NYSE: UIS) and Fluor Corporation (NYSE: FLR).

From 2009 through 2018, Mr. Sulpizio served as a director of CA, Inc. (NASDAQ: CA), an information technology management software company. He currently serves as an honorary board member of the advisory board of the University of California San Diego’s Sulpizio Family Cardiovascular Center.

He holds a Bachelor of Arts from California State University, Los Angeles, and a Master of Science in systems management from the University of Southern California.

Desney Tan has served as a ResMed director since November 2021, and is a member of the compensation committee.

Dr. Desney Tan is corporate vice president and managing director of the core Microsoft (NASDAQ: MSFT) Research Lab in Redmond, Washington. He was previously vice president and managing director for Health and Life Science R&D at Microsoft, where he’s worked in various leading research roles since 2004. He is also an affiliate professor of computer science and engineering at the University of Washington Seattle since 2007, where he co-founded the National Science Foundation Center for Sensorimotor Neural Engineering and chaired its industry advisory board.

Dr. Tan is a seasoned executive who has built and run multidisciplinary global innovation teams – leveraging expertise in hardware and devices, software development, applied machine learning and artificial intelligence, human-computer interaction, and applied science to make an impact in areas such as autonomous navigation, entertainment and consumer products, as well as health and life sciences.

Dr. Tan is the named inventor on more than 100 granted patents, and author of numerous academic publications on topics relevant to ResMed’s long-term strategy such as artificial intelligence, machine learning, and human-computer interaction. He serves on the Washington Research Foundation’s board of directors; as senior advisor and chief technologist to IntuitiveX, a medical device and life sciences innovation partner and catalyst; and as advisor to Proprio, which is developing an advanced surgical navigation platform. He achieved the rank of Lieutenant in the Singapore Armed Forces over two-and-a-half years of active-duty service, and still serves in its reserves.

Dr. Tan has a Ph.D. in computer science from Carnegie Mellon University, and a Bachelor of Science in computer engineering from the University of Notre Dame.

Ron Taylor has served as a ResMed director since January 2005 and its independent lead director since July 1, 2013. He is a member of the audit, compliance oversight and nominating & governance committees.

In 1987, Mr. Taylor founded Pyxis Corporation, a manufacturer of automated drug dispensers for hospitals, where he served as chairman, president, and CEO until its purchase by Cardinal Health, Inc., in 1996. For six years before founding Pyxis, Mr. Taylor was responsible for operations and international sales at Hybritech, Inc., a biotechnology company. Before joining Hybritech, he served for 10 years in management roles at Allergan plc (NYSE: AGN), a pharmaceutical company. From 1998-2001, he was a general partner at Enterprise Partners Venture Capital.

Mr. Taylor has served on the board of seven public companies, including Allergan and its predecessor companies from 1994 to 2018, and Red Lion Hotels from 1998 until 2014. He served as Chair of the compensation committee at both companies, as well as a member of the nominating and governance and audit committees. In addition he has been a director of 14 privately held companies. From 2002 until his appointment to the ResMed board in 2005, he served as chairman of the ResMed Foundation.

Mr. Taylor has a B.A. from the University of Saskatchewan and an M.A. from the University of California, Irvine.